髓系来源的抑制细胞在肝病发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2018.05.044

Abstract

Abstract: Myeloid derived suppressor cells （MDSC） are the kind of immature myeloid cells and progenitor cells from bone marrow. Recent studies found that MDSC were involved in the regulation of pathological changes of various liver diseases. This article systematically summarized the history,clustering and mechanism of MDSC,and the immunoregulatory effects of these cells in the pathogenesis and progression of various liver diseases.

Key words: Liver diseases, Myeloid derived suppressor cells, Immunoregulation

Gao Miaomiao, Zhang Jiyuan, Zou Zhengsheng.. Myeloid-derived suppressor cells in the pathogenesis of liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 813-816.

References

[1] Kong YY,Fuchsberger M, Xiang SD, et al.Myeloid derived suppressor cells and their role in diseases.Curr Med Chem,2013,20(11):1437-1444.
[2] Boros P,Ochando JC,Chen SH,et al.Myeloid-derived suppressor cells:natural regulators for transplant tolerance. Hum Immunol,2010,71(11):1061-1066.
[3] Talmadge JE,Gabrilovich DI.History of myeloid-derived suppressor cells. Nat Rev Cancer,2013,13(10):739-752.
[4] Laoui D,Van Overmeire E,Movahedi K,et al.Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology,2011,216(11):1192-1202.
[5] Serafini P,Carbley R,Noonan KA,et al.High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res,2004,64(17):6337-6343.
[6] Kowanetz M,Wu X,Lee J,et al.Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.Proc Natl Acad Sci U S A,2010,107(50):21248-21255.
[7] Jin H,Aiyer A,Su J,et al.A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature.J Clin Invest,2006,116(3):652-662.
[8] Delano MJ,Scumpia PO,Weinstein JS,et al.MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med,2007,204(6):1463-1474.
[9] Gabrilovich DI,Nagaraj S.Myeloid-derived suppressor cells as regulators of the immune system.Nat Rev Immunol,2009,9(3):162-174.
[10] Gabrilovich DI,Bronte V,Chen SH,et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res,2007,67(1):425;author reply 426.
[11] Youn JI,Nagaraj S,Collazo M,et al.Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol,2008,181(8):5791-5802.
[12] Dumitru CA,Moses K,Trellakis S,et al.Neutrophils and granulocytic myeloid-derived suppressor cells:immunophenotyping,cell biology and clinical relevance in human oncology. Cancer Immunol Immunother,2012,61(8):1155-1167.
[13] Rodriguez PC,Ernstoff MS,Hernandez C,et al.Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.Cancer Res,2009,69(4):1553-1560.
[14] Zhao F,Hoechst B, Duffy A, et al.S100A9 a new marker for monocytic human myeloid-derived suppressor cells.Immunology,2012,136(2):176-183.
[15] Mirza N, Fishman M, Fricke I, et al.All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res,2006,66(18):9299-9307.
[16] Nagaraj S,Gupta K, Pisarev V, et al.Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med,2007,13(7):828-835.
[17] Ostrand-Rosenberg S,Sinha P.Myeloid-derived suppressor cells:linking inflammation and cancer.J Immunol,2009,182(8):4499-4506.
[18] Srivastava MK,Sinha P,Clements VK,et al.Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.Cancer Res,2010,70(1):68-77.
[19] Serafini P,Mgebroff S,Noonan K,et al.Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.Cancer Res,2008,68(13):5439-5449.
[20] Li H,Han Y,Guo Q,et al.Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.J Immunol,2009,182(1):240-249.
[21] Nausch N,Galani IE,Schlecker E,et al.Mononuclear myeloid derived “suppressor” cells express RAE-1 and activate natural killer cells. Blood,2008,112(10):4080-4089.
[22] Shen P,Wang A,He M,et al.Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res,2014,44(6):639-650.
[23] Xu Y,Zhao W,Xu J,et al.Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2.Oncotarget,2016,7(8):8866-8878.
[24] Kapanadze T,Gamrekelashvili J,Ma C,et al.Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.J Hepatol,2013,59(5):1007-1013.
[25] Ma S,Cheng Q,Cai Y,et al.IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma.Cancer Res,2014,74(7):1969-1982.
[26] Hoechst B,Voigtlaender T,Ormandy L,et al.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology,2009,50(3):799-807.
[27] Hoechst B,Ormandy LA,Ballmaier M,et al.A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+)T cells.Gastroenterology,2008,135(1):234-243.
[28] Arihara F,Mizukoshi E,Kitahara M,et al.Increase in CD14+
HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.Cancer Immunol Immunother,2013,62(8):1421-1430.
[29] Chen S,Akbar S,Abe M,et al.Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol,2011,166(1):134-142.
[30] Kong X,Sun R,Chen Y,et al.Gammadelta T cells drive myeloid-
derived suppressor cell-mediated CD8+T cell exhaustion in hepatitis B virus-induced immunotolerance. J Immunol,2014,193(4):1645-1653.

Myeloid-derived suppressor cells in the pathogenesis of liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[2]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[3]	Wang Haifang, Yang Dawei, Jia Bei. Impact of nutrition support and medusa administration on liver function, erythrocyte and platelet parameters in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 381-384.
[4]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[5]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[6]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[7]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[8]	Guo Baona, Zhan Yutao.. Clinical features of alcoholic liver diseases:An analysis of 79 cases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 877-880.
[9]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[10]	Wang Dengbin. Progress of imaging technologies for diagnosis of liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 489-492.
[11]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[12]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.
[13]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.
[14]	Zhang Zhihua, Gu Tianyi, Chen Liuying, et al. Meta analysis of efficacy of ornithine aspartate in the treatment of patients with fatty liver [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 233-236.
[15]	Wang Yanxin, Yu Hongwei, Zhu Yueke. Nutritional assessment and treatment in patients with chronic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 317-320.